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Chronic kidney disease (CKD) represents the fastest growing pathology worldwide
with a prevalence of >10% in many countries. In addition, kidney cancer represents
5% of all new diagnosed cancers. As currently no effective therapies exist to restore
kidney function after CKD- as well as cancer-induced renal damage, it is important
to elucidate new regulators of kidney development and disease as new therapeutic
targets. G protein-coupled receptors (GPCRs) represent the most successful class of
pharmaceutical targets. In recent years adhesion GPCRs (aGPCRs), the second largest
GPCR family, gained significant attention as they are present on almost all mammalian
cells, are associated to a plethora of diseases and regulate important cellular processes.
aGPCRs regulate for example cell polarity, mitotic spindle orientation, cell migration,
and cell aggregation; all processes that play important roles in kidney development
and/or disease. Moreover, polycystin-1, a major regulator of kidney development and
disease, contains a GAIN domain, which is otherwise only found in aGPCRs. In this
review, we assess the potential of aGPCRs as therapeutic targets for kidney disease.
For this purpose we have summarized the available literature and analyzed data from the
databases The Human Protein Atlas, EURExpress, Nephroseq, FireBrowse, cBioPortal
for Cancer Genomics and the National Cancer Institute Genomic Data Commons
data portal (NCIGDC). Our data indicate that most aGPCRs are expressed in different
spatio-temporal patterns during kidney development and that altered aGPCR expression
is associated with a variety of kidney diseases including CKD, diabetic nephropathy, lupus
nephritis as well as renal cell carcinoma. We conclude that aGPCRs present a promising
new class of therapeutic targets and/or might be useful as diagnostic markers in kidney
disease.
Keywords: kidney, adhesion G protein-coupled receptor, renal cell carcinoma, chronic kidney disease, lupus
nephritis, diabetic nephropathy
KIDNEY FUNCTION
The main function of the kidney is to filter the blood while conserving water and maintaining the
electrolyte homeostasis. A part of the filtrate is excreted (e.g., urea, ammonium, uric acid, metabolic
waste, toxins) and another part is reabsorbed (e.g., solute-free water, sodium, bicarbonate, glucose,
calcium, phosphate, and amino acids). In addition, the kidney has other functions such as
gluconeogenesis, converting a precursor of vitamin D to its active form, and synthesizing the
hormones erythropoietin and renin. This way the kidney regulates the volume of various body fluid
compartments, fluid osmolality, acid-base balance, various electrolyte concentrations, removal of
toxins and participates in the intermediary metabolism.
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The structural and functional unit of the kidney is the nephron
which consists of a renal corpuscle and a renal tubule (Figure 1A;
Romagnani et al., 2013). The renal corpuscle contains a tuft of
capillaries (glomerulus) and the Bowman’s capsule. The renal
tubule extends from the capsule and has five anatomically and
functionally different segments: the proximal tubule (proximal
convoluted tubule followed by the proximal straight tubule),
the loop of Henle (descending and ascending loop), the distal
convoluted tubule, the connecting tubule, and the collecting
duct. Blood filtration occurs in the glomerulus through two cell
layers, fenestrated endothelial cells and podocytes, as well as their
individual laminae and the basal membrane they both share.
Resorption takes place via peritubular capillaries while the fluid
flows from the Bowman’s capsule down the tubule. The urine,
final product of blood filtration, runs from the collecting ducts
through the renal papillae, calyces, pelvis, and finally via the
ureter into the urinary bladder.
KIDNEY DEVELOPMENT
Due to different surrounding environments and thus different
requirements on renal function, kidneys passed through
different adaptive designs along evolution. Ultimately, this led
to the intricate structures in the mammalian kidney. The
kidney arises from the intermediate mesoderm and proceeds
through three successive developmental phases representing
different evolutionary patterns: pronephros, mesonephros, and
metanephros (Figure 1; Saxén et al., 1986). The first evidence
of kidney organogenesis is the formation of a primary nephric
(pronephric) duct. As it grows caudally, a linear array of epithelial
tubules forms and extends medioventrally giving rise to an
anterior rudimentary pronephros, in which the tubules are not
yet directly linked with the capillary tuft (Romagnani et al.,
2013). The pronephros (Figure 1A) is active in embryos of fish
and larvae of amphibians as well as in some adult primitive
fish. In more advanced vertebrates, the pronephros is frequently
nonfunctional and soon replaced by the mesonephros. The
anterior part of the pronephric duct degenerates while the
caudal portion persist and serves as the central component
of the excretory system (mesonephric or Wolffian duct). The
middle portion induces another set of tubules, the mesonephros
(Figure 1B), which is in mammals the source of hematopoietic
stem cells. Subsequently, the mesonephros either regresses or
becomes sperm-carrying tubes (epididymis, vas deferens and
seminal vesicles) in male individuals. In amphibians and most
fish the mesonephros represents the permanent kidney, while in
mammals, birds, and reptiles the mesonephros regresses and the
metanephros is formed.
The metanephros (Figure 1C) is the permanent kidney
in reptiles, birds, and mammals. It develops from a caudal
diverticulum of the Wolffian duct, which is induced to branch
by signals from the surrounding metanephric mesenchyme. This
epithelial branch is called ureteric bud (Schmidt-Ott et al.,
2005; Dressler, 2008). The ureteric bud epithelia proliferate,
migrate, and gradually invade the metanephric mesenchyme as it
undergoes branching morphogenesis (Watanabe and Costantini,
2004), which is mediated by glial-derived neurotrophic factor
(Gdnf). Gdnf is released by metanephric mesenchymal cells
and binds to the Ret receptor on epithelial ureteric bud cells
inducing migration, invasion and branching (Towers et al., 1998;
Costantini, 2010). In the end, the ureteric bud branches from the
collecting system of the kidney (bladder trigone, ureters, renal
pelvis, and collecting ducts), which is controlled by multiple
patterning factors such as c-Ret, Spry1, ETv5, Robo2, Sox9,
Wnt11, Angiotensin II, Fgfr2, Bmp4, At1r, FoxC2, and Pax2
(Yosypiv, 2008; Yosypiv et al., 2008; Reidy and Rosenblum,
2009; Faa et al., 2012). Surrounding the tips of the ureteric
bud, metanephric mesenchymal cells condensate and aggregate
into the so-called cap mesenchyme, a process mainly driven by
Pax2 and Wnt4 (Sariola, 2002; Figure 2). Afterwards, the cap
mesenchyme progressively undergoesmesenchymal-to-epithelial
transition (MET) forming the renal vesicles (Carroll et al.,
2005) via Wnt4, Lhx1, and Fgf8 signaling and downregulation
of Six2 and Cited2 expression (Kispert et al., 1998; Davies,
1999; Brunskill et al., 2008). Subsequently, the vesicles undergo
segmentation patterning followed by fusion with the ureteric
branches to form a uriniferous tubule (Georgas et al., 2009).
During the following development, renal vesicles change their
appearance and proceed through the stages comma-shaped body,
S-shaped body and capillary loop stage (Little et al., 2007). During
these stages, markers for proximal and distal tubules of the future
nephron start to be expressed, and the primitive glomeruli evolve
by incorporating vascular loops and allowing endothelial cells
to get in contact with visceral epithelial cells (early podocytes)
forming the glomerular filtration barrier. Transcription factors
such as Wt1 and Pod1 play a central role during this process
of morphogenesis (Rico et al., 2005). Interstitial cells and
vasculature are formed from a multipotent pool of progenitor
cells in the metanephric mesenchyme (Kispert et al., 1998).
RESEMBLANCE OF ADHESION G
PROTEIN-COUPLED RECEPTORS
(AGPCRS) AND POLYCYSTIN-1
aGPCRs represent one of five families of the GPCR superfamily,
the largest group of membrane receptors in eukaryotes. In
humans, the aGPCR family contains 33 members which can
be subdivided into 9 subfamilies (I to IX) (Hamann et al.,
2015). They are characterized by a long extracellular domain
which comprises several adhesion domains, a 7 transmembrane
domain and an intracellular domain. The extended N-terminus
can be cleaved in almost all aGPCRs at the so-called GPCR
proteolysis site (GPS) within the GPCR autoproteolysis-inducing
(GAIN) domain (Figure 3). This property permits a variety of
signaling modalities including activation of CTF-dependent or
-independent signals via agonist interactions at the NTF or the
CTF. In addition, NTF can bind either to partners at the surface
of a neighboring cell or the extracellular matrix. Yet, the NTF
can also be shed off to induce non-cell-autonomous signals in
neighboring or in distant cells (Langenhan et al., 2013; Patra et al.,
2013, 2014). However, some aGPCRs containing a GPS motif
do not undergo cleavage [e.g., ADGRC1 (CELSR1), ADGRF4
(GPR115), ADGRF2 (GPR111)]. ADGRA1 (GPR123) is the only
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FIGURE 1 | The kidney through evolution, as it proceeded through a series of successive phases, each marked by the development of a more advanced kidney: the
pronephros, mesonephros, and metanephros. (A) The pronephros is the most immature form of kidney; it represents the first stage of kidney development in most
animal species, but became functional only in ancient fish, such as lampreys or hagfish, or during the larval stage of amphibians. (B) The mesonephros represents the
second stage of kidney development in most animal species, and represents the functional mature kidney in most fish and amphibians. It is made up of an increased
number of nephrons, usually dozens to hundreds. (C) The metanephros represents the last stage of kidney development after degeneration of the pronephros and
mesonephros in reptiles, birds and mammals, where it persists as the definitive adult kidney; it consists of a substantially increased number of nephrons, usually from
thousands to millions. Romagnani et al. progenitors: an evolutionary conserved strategy for kidney regeneration. Reprinted by permission from Macmillan Publishers
Ltd: (Romagnani et al., 2013).
aGPCR that does not contain a GAIN domain (Hamann et al.,
2015).
GPCRs are of great clinical interest as they play an important
role in the development of pharmacological-based therapies
(Lagerström and Schiöth, 2008; Nieto Gutierrez and McDonald,
2017). In addition, aGPCRs are widely expressed (Hamann
et al., 2015), play critical roles in many developmental processes
(Luo et al., 2011; Geng et al., 2013; Ludwig et al., 2016; Musa
et al., 2016; Sigoillot et al., 2016), and are also involved in a
variety of diseases. For example, aGPCRs are involved in the
control of innate effector functions and the susceptibility for
and onset of (auto)inflammatory conditions (Lin et al., 2017),
in tumorigenesis (Aust et al., 2016), and pulmonary disease
(Ludwig et al., 2016), and they are linked to psychiatric disorders
(Lanoue et al., 2013). Yet, little is known about the downstream
signaling mechanisms of aGPCRs. In recent years, however,
evidence has been provided that aGPCRs can control cell polarity
(Strutt et al., 2016), mitotic spindle orientation (Müller et al.,
2015), cell migration (Valtcheva et al., 2013; Strutt et al., 2016),
and cell aggregation (Hsiao et al., 2011) and that they serve as
mechanosensors (Scholz et al., 2016). These are all processes that
also play important roles in kidney development and disturbance
of these processes are known to contribute to kidney disease
(Sariola, 2002; Schordan et al., 2011; Cabral and Garvin, 2014;
Xia et al., 2015; Gao et al., 2017; Kunimoto et al., 2017). Thus,
we wondered whether also aGPCRs might play a role in renal
physiology and pathophysiology to determine their potential as
therapeutic targets for kidney disease.
As detailed below, the importance of aGPCRs in kidney
development is underlined by initial reports in the literature.
Moreover, it is intriguing that the 11 transmembrane domain
receptor polycystin-1, a major regulator of kidney development
and disease, is the only GAIN-domain containing protein known
so far that does not belong to the aGPCR family (Cai et al.,
2014). Polycystin-1 plays a role in renal tubular development
and functions in a complex with polycystin-2 as a fluid shear
sensor. Mutations in the corresponding genes, Pkd1 and Pkd2,
have been associated with autosomal dominant polycystic kidney
disease (ADPKD) (Ferreira et al., 2015). Furthermore, it has been
shown that autoproteolytic cleavage at a GPS motif is required
for polycystin-1 trafficking to cilia and that only a cleavable form
of polycystin-1 can rescue the embryonically lethal Pkd1-null
mutation in mice (Cai et al., 2014).
SEARCH STRATEGY
In order to determine what has so far been made publically
available in regards to the role of aGPCRs in kidney development
and disease, we performed a literature search using Pubmed
(https://www.ncbi.nlm.nih.gov/pubmed/). Search terms included
“kidney” or “renal,” “development,” “disease” and/or the official
or alternative individual names of every aGPCR. In addition,
we cross-checked our literature search results with the literature
information available in the IUPHAR/BPS database (http://
www.guidetopharmacology.org/). Moreover, we performed a
comprehensive search utilizing Google Scholar (https://scholar.
google.de/), Google (https://www.google.de/) and Google images
(https://images.google.de/). Finally, we analyzed the following
databases:
The Human Protein Atlas (https://www.proteinatlas.org/).
The Human Protein Atlas (HPA) is a Swedish-based program
that aims “to map all the human proteins in cells, tissues
and organs using integration of various Omics technologies,
including antibody-based imaging, mass spectrometry-based
proteomics, transcriptomics and systems biology” (Uhlén et al.,
2015; Uhlen et al., 2017; Thul et al., 2017). For our review
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FIGURE 2 | Phases of nephron development in all animals. The metanephric
mesenchyme condenses around the ureteric bud and is induced to convert
into epithelium and generates in sequence a vesicle and an S-shaped body.
Then, the S-shaped body becomes invaded by blood vessels at one extremity
and elongates and segmentates at the other, thus generating the whole
nephron. This sequence of events is similar during development across all
animal species. Reprinted by permission from Macmillan Publishers Ltd:
(Romagnani et al., 2013).
we utilized the “Tissue Atlas” that shows the distribution of
proteins across all major tissues and organs in the human body
including the kidney. The provided data are based on RNAseq
and immunohistochemistry on tissue microarrays revealing
spatial distribution, cell type specificity and the rough relative
abundance of proteins in these tissues.
EURExpress (http://www.eurexpress.org/ee/) (Diez-Roux
et al., 2011). The EURExpress database provides RNA expression
patterns by means of in situ hybridization on paraffin-embedded
sections, gelatin-embedded sections and cryosections from
E14.5 wild type murine embryos. For some genes, data are also
available for other embryonic stages. Note, that this database
is not fully annotated, fails to indicate in several cases organs
exhibiting a positive expression signal, and does not always
provide the necessary resolution to associate the expression
pattern with a distinct cell type.
Nephroseq (https://www.nephroseq.org/resource/login.html)
(November 2017, University of Michigan, Ann Arbor, MI).
Nephroseq is a platform that allows integrative data mining of
publicly available renal developmental (human) as well as renal
disease (model as well as clinical) gene expression data sets
which are gathered and curated by an experienced team of data
scientists, bioinformaticians, and nephrologists. Thus, it allows
identifying genes associated with known disease phenotypes to
FIGURE 3 | Adhesion G protein-coupled receptors possess structural
elements of adhesion molecules and GPCRs. Their extended extracellular
domain (ECD) usually contains a collection of adhesion motifs that can engage
with cellular and matricellular interaction partners, and a juxtamembrane
GPCR autoproteolysis-inducing (GAIN) domain, which is present in all
aGPCRs. GAIN subdomain A (yellow rectangle), GAIN subdomain B (pink
rectangle) and the GPCR proteolysis site (GPS) motif (pink and orange
semicircles) are shown. The GAIN domain is directly connected to the
seven-transmembrane (7TM) unit through a linker sequence of approximately
20 amino acids, known as the Stachel (stalk). Recently, this structural
component of aGPCRs was identified as a tethered agonist, which stimulates
metabotropic activity of several aGPCR homologs. Similar to the ECD, the
intracellular domains (ICDs) of aGPCRs can be unusually large. It is estimated
that more than one-half of all known aGPCRs undergo auto-proteolytic
cleavage that is catalyzed through the GAIN domain, which is present on the
cell surface as a non-covalent heterodimer between an amino-terminal
fragment (NTF) and a carboxy-terminal fragment (CTF). The cleavage occurs at
the evolutionarily highly conserved GPS. Reprinted by permission from
Macmillan Publishers Ltd: (Langenhan et al., 2016).
obtain a better understanding of its role in renal physiology and
pathophysiology. In regards to healthy adult kidneys it provides
microarray-based information from 5 samples regarding the
enrichment of a gene in one of the following compartments:
glomeruli, inner renal cortex, inner renal medulla, outer renal
cortex, outer renal medulla, papillary tips, and renal pelvis
(Higgins et al., 2004). Here, we considered genes as significantly
regulated if the p-value was <0.05.
FireBrowse (http://firebrowse.org/). FireBrowse is a platform
that enables an efficient analysis of a possible association of a
candidate gene with cancer based on DNA and RNA sequence
data. The platform accesses Broad Institute’s TCGA (The Cancer
Genome Atlas) GDAC (Genome Data Analysis Center) Firehose
database, “one of the deepest andmost integratively characterized
open cancer datasets in the world” (over 80,000 sample aliquots
from >11,000 cancer patients, spanning 38 unique disease
cohorts). Here, we highlight information on >2.5-fold change of
RNA expression. Note, no p-values are available.
cBioPortal for Cancer Genomics (http://www.cbioportal.org/)
(Cerami et al., 2012; Gao et al., 2013). cBioPortal (cBio) is
another platform based on TCGA to associate candidate genes
with cancer based on data from 168 cancer studies. It comprises
DNA copy-number data, mRNA andmicroRNA expression data,
non-synonymous mutations, protein-level and phosphoprotein
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level (RPPA) data, DNA methylation data, and limited de-
identified clinical data.
National Cancer Institute Genomic Data Commons data
portal (NCIGDC) (https://portal.gdc.cancer.gov/). Similar to the
two databases above, NCIGDC allows based on TCGA the
association of candidate genes with cancer based on 32,555
cases. Data are provided for 22,144 genes including 3,115,606
mutations.
Our analysis revealed that the majority of the 33 human
aGPCRs and several orthologues have been in some aspect related
to kidney development or disease (Tables 1, 2) as detailed below.
AGPCRS IN KIDNEY DEVELOPMENT
Adgrc1 (Celsr1) Is Required for Ureteric
Bud Branching
The best characterized aGPCR in regards to its function during
kidney development is Adgrc1 (Celsr1). Yates and co-workers
demonstrated in 2010 that Adgrc1 and Vangl2 are required for
normal lung branching morphogenesis (Yates et al., 2010b). In
the same year they reported furthermore that Vangl2 is required
for mammalian kidney-branching morphogenesis (Yates et al.,
2010a). In this manuscript they also described Adgrc1 expression
in podocytes, proximal tubular cells, collecting duct stalks
and S-shaped bodies in the nephrogenic cortex of E18.5
mouse embryos. The study was based on an antibody
whose specificity was validated by utilizing loss-of-function
Celsr1Crsh/Crsh embryos (Yates et al., 2010b). Yet, the authors did
not analyze the role of Adgrc1 during kidney development. Data
from the EURExpress database (Diez-Roux et al., 2011), released
in 2011, suggest that Adgrc1 is expressed at E14.5 in mice and
further indicated that Adgrc1 plays a role in kidney development.
Finally, Bróska and co-workers demonstrated in 2016 thatAdgrc1
is required, in association with the planar cell polarity gene
Vangl2, for ureteric bud branching (Brzoska et al., 2016). Mice
carryingmutations inAdgrc1 (Celsr1Crsh/Crsh andCelsr1Crsh/+) or
Vangl2 (Vangl2Lp/+) exhibited branching defects in the ureteric
tree at E13.5, which were more severe in Celsr1Crsh/+:Vangl2Lp/+
mice. At E17.5 kidneys exhibited overall growth retardation
(Celsr1Crsh/+:Vangl2Lp/+ > Celsr1Crsh/Crsh > Celsr1Crsh/+) and
histological analysis revealed mitotic spindle misorientation
(along the longitudinal axis of the kidney tubules), dilation of
cortical tubules in Celsr1Crsh/Crsh mutants and an up-regulation
of Gdnf and Ret mRNA levels in the Celsr1Crsh/+:Vangl2Lp/+
mutants. It is noteworthy that cleavage of Adgrc1 at its GPSmotif
has so far not been reported (Formstone et al., 2010; Hamann
et al., 2015). Thus, GPS-based cleavage of Adgrc1 seems not to
play a role in kidney development.
During adult renal physiology, Adgrc1 seems not to play a
major role as none of the databases indicates its expression in
adult renal cells. In adult zebrafish, a low expression of theAdgrc1
homolog adgrc1a (celsr1a) has been described in the kidney
compared to the expression level in whole embryos at 10 h post
fertilization (hpf) based on quantitative real-time PCR (Harty
et al., 2015). However, considering only the expression levels
in the investigated adult zebrafish organs (6 months), adgrc1a
is markedly enriched in kidney, intestine, and skin compared
to brain, eye, heart, liver, skeletal muscle, ovaries and testis
(Harty et al., 2015). The only information available in the utilized
developmental databases is that ADGRC1 is expressed in renal
vessels (HPA database).
aGPCRs Strongly Correlated to Renal
Development
In this section, we discuss aGPCRs whose correlation to kidney
development is strongly supported by data of several databases.
Adgrg6 (Gpr126)
Plays an essential role in neural, cardiac and ear development
(Patra et al., 2014) as well as cartilage biology and spinal
column development (Karner et al., 2015). The exact role and
underlying signalingmechanism is still poorly understood.While
no publication described so far the expression of Adgrg6 during
kidney development, in situ hybridization data available from the
EURExpress database suggest that Adgrg6 is expressed in E14.5
mouse embryos in the outgrowing ureteric bud branches of the
metanephros (sections 9–12, 18–21). A possible renal function
of Adgrg6 is further supported by its RNA expression in the
adult kidney of zebrafish (Harty et al., 2015) and humans (HPA
database, vessels). Harty and coworkers revealed that adgrg6
(gpr126) expression in the adult zebrafish kidney is comparable
to the maximal expression level observed during development (3
days post fertilization, 3 dpf). adgrg6was only higher expressed in
adult skeletal muscle (around 4 times enriched). Moreover, data
from the Nephroseq database confirm the ADGRG6 expression
in the human kidney suggesting that it is enriched in the
renal pelvis, which arises from the outgrowing ureteric bud
branches. Similarly, Pradervand and coworkers published that
Adgrg6 is enriched in the cortical portion of the collecting duct
in mice compared to the expression in the distal convoluted
tubule and the connecting tubule based on microarray-based
gene expression profiles (Pradervand et al., 2010). Collectively,
the available data for Adgrg6 suggest that it is expressed during
kidney development as well as adulthood, being enriched in
collecting duct cells. However, the described data are all RNA-
based data as currently no reliable protein expression data
are available. Moreover, no kidney phenotype has so far been
described in Adgrg6 knockout mice, neither in the lines that are
embryonic lethal at E11.5 (Patra et al., 2013) nor in Taconic
knockouts of which some are born alive (Monk et al., 2011).
Currently, we are utilizing our model systems (Patra et al.,
2013) including conditional mouse lines (Mogha et al., 2013)
to determine if the role of Adgrg6 might be underestimated in
kidney development.
Adgre5 (CD97)
Is an activation-associated leukocyte antigen suggested to act as
an adhesion molecule (Hamann et al., 2000). The association of
Adgre5 with the decay accelerating factor (DAF) prevents cells
from complement-mediated attack and therefore it is of great
importance in the study of autoimmunity and graft rejection
(Toomey et al., 2014). Already in 1999 first evidence, based on
Northern blot analysis, was provided that Adgre5 is expressed
in the adult mouse kidney (Qian et al., 1999). A possible role of
Frontiers in Cell and Developmental Biology | www.frontiersin.org 5 February 2018 | Volume 6 | Article 9
Cazorla-Vázquez and Engel Adhesion GPCRs in the Kidney
TABLE 1 | Adhesion GPCRs associated to kidney development.
aGPCR References Database Expression Spatio-temporal information Gain/loss of function Function/phenotype
Adgrl1 Masiero et al., 2013 HPA IHC, NB adult (human: tubules) - -
Adgrl2 Sugita et al., 1998;
Ichtchenko et al., 1999;
Masiero et al., 2013
- NB adult (human, rat) - -
Adgrl3 - HPA, NS IHC, microarray adult (human: tubules,
glomerulus)
- -
Adgrl4 Nie et al., 2012 EX, HPA IF, IHC, ISH, reporter
line
embryonic (E10.5 mouse:
vessels; E14.5 mouse), adult
(human vessels)
KO and double KO mouse
(with Adgrf5)
glomerular thrombotic
angiopathy
Adgre1 - NS microarray adult (human: glomerulus) - -
Adgre2 - - - - - -
Adgre3 HPA IHC adult (human: tubular cells) - -
Adgre4 - - - - - -
Adgre5 Hamann et al., 1996;
Qian et al., 1999; de la
Lastra et al., 2003;
Formstone et al., 2010;
Toomey et al., 2014
HPA, NS IF, IHC, NB, RT-PCR,
microarray, reporter line
embryonic (E14.5 mouse:
collecting system), juvenile
(4-month-old mouse: podocytes,
mesangial cells), adult (zebrafish/
pig/ human: glomerulus, pelvis/
mouse: mesangial cells)
KO mouse -
Adgra1 Formstone et al., 2010 - RT-PCR adult (zebrafish) - -
Adgra2 Huang et al., 2008 EX, NS ISH, RT-PCR,
microarray
embryonic (E14.5 mouse), adult
(rat/ human: pelvis)
- -
Adgra3 - EX, HPA IHC, ISH embryonic (E14.5 mouse:
nephrogenic cortex), adult
(human: tubular cells)
- -
Adgrc1 Formstone et al., 2010;
Yates et al., 2010a;
Brzoska et al., 2016
EX, HPA IF, IHC, ISH, RT-PCR embryonic (E14.5 mouse, E18.5
mouse: podocytes, proximal
tubule, collecting duct stalks,
S-shaped body); adult (zebrafish/
human: vessels)
Mice carrying a loss of
function mutation
ureteric bud branching
Adgrc2 - EX, HPA, NS IHC, ISH, microarray embryonic (E14.5 mouse), adult
(human: medulla)
- -
Adgrc3 - - - - - -
Adgrd1 - - - - - -
Adgrd2 - - - - - -
Adgrf1 Alva et al., 2006;
Prömel et al., 2012
HPA, NS IHC, RT-PCR,
microarray, reporter line
adult (human: glomerulus,
papillary tips)
KO mouse -
Adgrf2 - - - - - -
Adgrf3 - NS microarray adult (human: glomerulus) - -
Adgrf4 Alva et al., 2006 - RT-PCR, reporter line - KO mouse -
Adgrf5 Alva et al., 2006; Nie
et al., 2012
NS IF, RT-PCR, microarray embryonic (E12.5 mouse:
vessels), adult (human: cortex,
medulla, papillary tips/ mouse:
glomerulus)
KO and double KO mouse
(with Adgrl4)
glomerular thrombotic
angiopathy
Adgrb1 Calderón-Zamora
et al., 2017
- IHC, RT-PCR adult (human) - -
Adgrb2 - HPA, NS IHC, microarray adult (human: tubules, pelvis) - -
Adgrb3 - NS microarray adult (human: glomerulus) - -
Adgrg1 Matsushita et al., 1999;
Shashidhar et al., 2005
EX, NS ISH, NB, WB,
microarray
embryonic (E12 mouse: ureteric
branches), adult (human: cortex)
- -
Adgrg2 - - - - - -
Adgrg3 Formstone et al., 2010 - RT-PCR adult (zebrafish) - -
Adgrg4 - NS microarray adult (human: glomerulus) - -
Adgrg5 - HPA IHC adult (human: tubular cells) - -
(Continued)
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TABLE 1 | Continued
aGPCR References Database Expression Spatio-temporal information Gain/loss of function Function/phenotype
Adgrg6 Formstone et al., 2010;
Karner et al., 2015
EX, HPA, NS IHC, ISH, RT-PCR,
microarray
embryonic (E14.5 mouse:
collecting system), adult (human:
pelvis, vessels/ mouse: cortical
collecting duct/ zebrafish)
- -
Adgrg7 Formstone et al., 2010 - RT-PCR adult (zebrafish) - -
Adgrv1 - HPA, NS IHC, microarray adult (human: medulla) - -
EX, EURExpress; HPA, The Human Protein Atlas; NS, Nephroseq; IF, immunofluorescence; IHC, immunohistochemistry; ISH, in situ hybridization; NB, Northern blot; RT-PCR, real-time
PCR; WB, Western blot.
Adgre5 in adult kidney physiology was further supported by the
detection of Adgre5 RNA in adult porcine kidney (de la Lastra
et al., 2003), strong expression in adult zebrafish kidney [homolog
adgre5a (cd97a)] (Harty et al., 2015), and more importantly by
the detection of Adgre5 protein in intraglomerular mesangial
cells of the adult mouse kidney (Jaspars et al., 2001) utilizing
validated monoclonal antibodies (Hamann et al., 1996). In
2008, the analysis of a LacZ knockin reporter mouse line in
combination with desmin expression analysis demonstrated that
Adgre5 is expressed in podocytes and mesangial cells of 4
months-old mice (Veninga et al., 2008). This is in agreement with
data from the Nephroseq database that indicates that ADGRE5
is enriched in the adult human glomerulus and renal pelvis. Yet,
also despite a strong expression signal forAdgre5 in the collecting
duct system of E14.5 mouse embryos (EURExpress, sections 9–
11, 18–21), 4 months-oldAdgre5 knockout mice showed no overt
phenotype in the analyzed organs, including the kidney.
Subfamily VI
First evidence for a role of these family members during
kidney physiology was provided by Abe and coworkers in
1999. They demonstrated by Northern blot analysis that Adgrf5
(Gpr116/Ig-Hepta) is at low levels expressed in the adult rat
kidney and identified by immunohistochemistry intercalated
cells of the cortical collecting duct as the origin of expression
(Abe et al., 1999). Previously, it has been demonstrated that
it has a well-established role in lung surfactant homeostasis
and that its deletion results in glucose intolerance and insulin
resistance as well as a subtle vascular phenotype (Nie et al.,
2012; Bridges et al., 2013; Fukuzawa et al., 2013; Yang et al.,
2013; Niaudet et al., 2015). According to the Nephroseq database,
ADGRF5 is also expressed in the adult human kidney. Recently,
transgenic mice expressing mCherry under the control of the
Adgrf5 promoter (Gpr116-mCherry) as well as knockout mice
were generated (Lu et al., 2017). The analysis of 8 weeks-old
reporter mice revealed that Adgrf5 is expressed in endothelial
cells of the microvessels in different organs. In the kidney,
Adgrf5 expression was also detected in microvessels and in
glomeruli exclusively in endothelial cells and not in mesangial
cells or podocytes. The previously described expression in
intercalated cells of the cortical collecting duct was not
confirmed. While Adgrf5 knockout mice exhibited no obvious
renal phenotype, Adgrf5/Adgrl4 (Eltd1) double knockout mice
exhibited a hemolysis phenotype (Lu et al., 2017). In addition,
these mice exhibited proteinuria as well as uremia indicating
kidney failure. This was correlated to increased mesangial matrix
and a damaged glomerular filtration barrier including loss of
endothelial fenestration and fusion of podocytes foot processes.
Minor albuminuria was already detected at birth. The authors
concluded that Adgrf5/Adgrl4 double knockout mice exhibit
glomerular thrombotic microangiopathy. Note, Adgrl4 knockout
mice exhibited no obvious kidney phenotype. Moreover,
endothelial-specific deletion of Adgrf5/Adgrl4 utilizing VE-Cad-
Cre mice, which are known to induce recombination in the
endothelium of arteries and capillaries of the glomerulus of adult
kidneys (Alva et al., 2006), resulted in no renal phenotype.
Prömel and coworkers investigated in 2012 by RT-PCR the
expression of most members of subfamily VI [Adgrf1 (Gpr110),
Adgrf2 (Gpr111), Adgrf4 (Gpr115), and Adgrf5]. They observed
based on this analysis that Adgrf1 is strongly expressed in the
adult mouse kidney (Prömel et al., 2012), confirming previous
data by Lum and coworkers demonstrating ADGRF1 expression
in the adult human kidney (Lum et al., 2010). In addition
they detected very weak expression levels of Adgrf4 (abundantly
expressed in the skin) and Adgrf5 (most abundantly expressed
in lung, liver, and heart). No or at best faint expression was
detected forAdgrf2. Subsequently, they generated reportermouse
lines and knockout mice for loss-of-function studies for Adgrf1,
Adgrf2, and Adgrf4. The analysis of these mouse lines revealed
strong expression of Adgrf1 in the adult renal pelvis and ureter.
ForAdgrf2 andAdgrf4 no conclusive data were provided. Despite
some indications of renal expression, the authors detected in
none of the generated knockout mouse lines an obvious renal
phenotype. According to the Nephroseq database, ADGRF1
is enriched in the papillary tips, ADGRF3 (GPR113) in the
glomerulus, and ADGRF5 in all renal structures, except for the
pelvis, of the adult human kidney.
aGPCRs Weakly Correlated to Renal
Development
In this section, we discuss aGPCRs for which data are available
but not sufficient, or even contradictory, to draw a strong
conclusion in regards to a kidney-specific function.
Subfamily I
Like Adgrf5, Adgrl4 is expressed in endothelial cells (Lu et al.,
2017). Initially, it was described as a receptor upregulated
in the adult heart (Nechiporuk et al., 2001). Subsequently,
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TABLE 2 | Adhesion GPCRs associated to kidney disease.
aGPCR
member
References Nephroseq (x-fold) FireBrowse (x-fold) NCIGDC cBio
ccRCC chRCC pRCC
Adgrl1 - mDN (1.596) 0.420 1.870 0.919 - -
Adgrl2 - IgA (1.734), DN (1.791), LN
(2.228) CKD (2.204)
1.060 0.867 0.766 - -
Adgrl3 - - 0.590 0.124 0.076 - -
Adgrl4 Nie et al., 2012 IgA (2.757), LN (2.493), mDN
(1.525)
2.130 0.405 0.179 - chRCC (11%)
Adgre1 - DN (1.566), mDN (1.654), mLN
(3.238)
7.740 1.95 3.210 - -
Adgre2 - V (1.718), LN (1.756) 5.750 1.110 2.270 - -
Adgre3 - CKD (5.716) 1.920 0.518 2.510 - -
Adgre4 - CKD (6.363) - - - - -
Adgre5 - IgA (2.243), DN (2.488), V (2.278)
HT (2.132), FSGS (2.121)
MCD (1.642), LN (2.264)
MG (1.645)
2.550 0.336 1.960 - -
Adgra1 - CKD (5.460), mDN (3.564) 0.081 1.390 0.138 - -
Adgra2 - APOL1 (1.526) 2.920 0.754 0.219 - -
Adgra3 - CKD (2.253), APOL1 (1.905) 0.857 0.476 1.840 - chRCC (15%)
Adgrc1 - - 1.090 0.176 0.871 ccRCC (11%)
pRCC (10%)
ccRCC (15%)
Adgrc2 - - 0.577 0.199 0.709 - -
Adgrc3 - - 2.190 3.060 4.770 ccRCC (12%)
pRCC (10%)
chRCC (15%)
Adgrd1 - mDN (1.630) 0.288 0.073 0.325 - -
Adgrd2 - CKD (2.294) 1.220 - 1.870 - -
Adgrf1 - mDN (2.708), CKD (5.413) 0.002 0.544 0.146 - -
Adgrf2 - CKD (6.115) 0.966 0.084 2.560 - -
Adgrf3 - - 0.050 0.160 0.099 - -
Adgrf4 - CKD (5.402) 2.150 0.118 3.310 - chRCC (11%)
Adgrf5 Nie et al., 2012 - 0.702 1.600 0.056 - -
Adgrb1 Calderón-Zamora et al.,
2017; Mathema and
Na-Bangchang, 2017
- 0.910 0.010 1.040 - chRCC (11%)
Adgrb2 - CKD (1.786) 0.424 0.355 2.110 - chRCC (14%)
Adgrb3 - CKD (3.092) 0.169 0.052 0.240 - -
Adgrg1 - FSGS (3.100), CKD (2.189),
mDN (2.145)
0.703 3.890 0.476 - -
Adgrg2 Kudo et al., 2007 DN (1.701), CKD (4.762), mDN
(2.221), mLN (2.832)
2.340 1.180 0.413 - chRCC (11%)
Adgrg3 Wang et al., 2013 mDN (2.938) 2.230 3.890 1.610 - -
Adgrg4 - CKD (4.004) 1.160 0.539 1.490 - -
Adgrg5 - CKD (1.605) 2.410 0.941 2.100 - -
Adgrg6 - DN (1.942), CKD (3.872), mLN
(1.700)
1.900 0.418 2.00 - -
Adgrg7 - CKD (5.656) 1.990 2.080 1.970 - -
Adgrv1 - CKD (6.362) 0.072 0.399 0.028 ccRCC (16%)
pRCC (19%)
chRCC (11%)
APOL1, APOL1-associated kidney disease; ccRCC, clear cell renal cell carcinoma; chRCC, chromophobe renal cell carcinoma; CKD, chronic kidney disease; DN, diabetic nephropathy;
FSGS, focal segmental glomerulosclerosis; HT, hypertension-injured kidney; IgA, IgA nephropathy; LN, lupus nephritis; MCD, minimal change disease; mDN, mouse model of diabetic
nephropathy; MG, membranous glomerulopathy; mLN, mouse Berthier model of lupus nephritis with proteinuria; pRCC, papillary renal cell carcinoma; V, vasculitis-injured kidney; red
boxes, <2.5-fold downregulation; green boxes, >2.5-fold upregulation.
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it has been shown to counteract pressure overload-induced
myocardial hypertrophy (Xiao et al., 2012) and to regulate
tumor angiogenesis (Masiero et al., 2013). During early mouse
development, Adgrl4 is detected in the heart endocardium,
different regions of the brain and in the developing metanephros
of E14.5 mice, according to EURExpress (sections 5–8, 14–17).
The analysis of reporter mice revealed, similarly to Adgrf5, that
Adgrl4 is expressed in the adult microvasculature and in the
kidney exclusively in endothelial cells and not in mesangial
cells or podocytes of the glomeruli. In contrast to Adgrl4, little
information is available for the other subfamily members. Based
on Northern blot analysis it has been suggested that ADGRL1
(LPHN1) (Sugita et al., 1998) and ADGRL2 (LPHN2) (Sugita
et al., 1998; Ichtchenko et al., 1999) are expressed in the adult
human kidney. Analysis of RNA from adult rat kidneys suggests
at best a very low level of expression of Adgrl1 (compared
to brain) and Adgrl2 (compared to brain, lung and liver)
(Matsushita et al., 1999).
Adgrg1 (Gpr56)
According to the analyzed databases, Adgrg1 is low expressed in
E12.5 mouse ureteric branches (EURExpress, sections 10–13 and
19–22 of the template T60042 in sagittal section) and enriched
in the renal cortex of human adult kidneys (Nephroseq). The
expression of ADGRG1 in the adult human kidney has further
been supported by published Northern blot (Shashidhar et al.,
2005) and western blot data (Huang et al., 2008). Yet, no renal
phenotype has been described so far for Adgrg1 knockout mice
(Huang et al., 2008).
Adgra2 (Gpr124)
Recently, Calderon-Zamora and co-workers have described that
Adgra2 is expressed onmRNA level (RT-PCR) in the adult kidney
of normotensive and hypertensive rats (Calderón-Zamora et al.,
2017). A possible role of Adgra2 during kidney development
and adult renal physiology is further supported by data from
the databases EURExpress (sections 8–10, 16–18) and Nephroseq
(enriched in adult renal pelvis).
Adgrb1 (Bai1)
Izutsu and coworkers demonstrated by quantitative RT-PCR and
immunohistochemistry that ADGRB1 is expressed on mRNA
and protein level in the kidney with prominent expression in
proximal and distal tubules (Izutsu et al., 2011).
The databases EURExpress and Nephroseq also suggest
a possible role for Adgrc2 (Celsr2) in kidney development
and physiology (widely expressed, sections 5, 7–10, 17–19;
enriched in human adult medulla). In addition, the databases
EURExpress and HPA suggest a possible role for Adgra3
(Gpr125) (nephrogenic cortex, sections 6–10, 17, 19, 20; low
protein expression in adult human tubules).
The Nephroseq database further suggests that ADGRE1
(EMR1), ADGRB3 (BAI3), and ADGRG4 (GPR112) are
enriched in the glomerulus, ADGRB2 (BAI2) in the renal pelvis,
and ADGRV1 (GPR98) in the medulla of the adult human
kidney. The HPA database indicates that ADGRG5 (GPR114) is
expressed at low levels in tubules.
Finally, the analysis of aGPCRs during zebrafish development
suggests that also adgra1l (gpr123l) (most abundant in kidney
and skeletal muscle), adgrg3 (gpr97) (strongly expressed during
adulthood in most organs), and adgrg7b (gpr128b) (markedly
higher expressed in the adult kidney than in any other adult organ
or at any other developmental stage) are expressed in the adult
zebrafish kidney.
CONCLUSION I
Our analysis of publicly available data revealed that the role of
aGPCRs during kidney development and physiology is poorly
characterized. Yet, a plethora of descriptive data indicates that
a large number of aGPCRs are expressed in the kidney from
zebrafish to humans in a variety of cell-type specific expression
patterns. As most of the available data are based on RNA or
“Omics” approaches and as limited information is provided
on temporal expression patterns, it is important to validate
expression on protein level and to perform detailed spatio-
temporal expression analyses. Furthermore, it is fundamental
to characterize in detail the available knockout mouse lines for
renal phenotypes. Hereby, it should be considered that aGPCRs
might have overlapping functions and thus, due to the high
number of expressed aGPCR members in the kidney, it might be
necessary to utilize double knockout mice (e.g., Adgrf5/Adgrl4)
to elucidate the function of aGPCRs during kidney development
and physiology.
KIDNEY DISEASE AND CANCER
Chronic kidney disease (CKD) represents the fastest growing
pathology worldwide (Kam Tao Li et al., 2013) with an increase of
over 90% from 1990 to 2010 (Lozano et al., 2012). The prevalence
of CKD is in many countries >10% (Ortiz et al., 2014; Mills
et al., 2015). Independent of the original cause of impaired
renal function (e.g., diabetes mellitus, 30–40%; hypertension,
20%; inflammation of the glomeruli (glomerulonephritis), 13%;
interstitial nephritis, 10%; polycystic kidney disease, 6%) the
common final outcome of almost all progressive CKDs is
renal fibrosis (Liu, 2011; Humphreys, 2017). CKDs represent
an important risk factor for cardiovascular or cerebrovascular
diseases and progress toward end-stage renal disease (ESRD)
(Eckardt et al., 2013; Balogun et al., 2017), which can only be
treated by renal replacement therapies (RRT) like hemodialysis,
peritoneal dialysis, or transplantation (Eckardt et al., 2013). Yet,
despite improvements in immunosuppressive medications and
renal allograft survival, there is an increasing shortage of available
donor kidneys. For example, from 2003 to 2013, the number
of patients waiting for a kidney transplant has doubled in the
United States. This is mainly due to the fact that diabetes,
historically the most common cause of ESRD, is now the fastest
rising cause of ESRD (McCullough et al., 2009; Matas et al.,
2015). The standard therapy of CKD is antiproteinuric treatment
mostly by blockade of the renin-angiotensin system and the
management of blood pressure as well as blood glucose levels.
This therapeutic regimen slows the progression of the disease,
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but it cannot reverse or functionally repair the damage, or at
least stop progression. In addition, the effect of this regimen
depends significantly on the stage of CKDs. In recent years,
therefore, new strategies have been proposed for the treatment
of CKD that focus on several factors that have been linked to the
progression of kidney disease. The main focus is on drugs that
have anti-inflammatory and anti-fibrotic effects. At present, these
drugs are being tested with the aim of preserving kidney function
(Pena-Polanco and Fried, 2016).
Besides CKD, kidney cancer represents a significant socio-
economic challenge. Every year around 64,000 patients in the
United States and approximately 115,000 patients in Europe
are diagnosed with kidney cancer representing 5% of all new
diagnosed cancers. In addition, kidney cancer causes yearly in
the United States and in Europe nearly 15,000 and 49,000 deaths,
respectively (Siegel et al., 2017). The most common kidney
tumor is the renal cell carcinoma (RCC) comprising 80% to 90%
of all malignant kidney tumors and 70–80% of all solid renal
tumors (Ljungberg et al., 2011; Ridge et al., 2014). It originates
from the epithelial tubular cells. RCC is characterized by an
asymptomatic disease course and thus is often diagnosed late
explaining the high mortality rates. It needs to be noted that
during the last years it has been recognized that renal cell tumors
are more heterogeneous on a histologically and molecularly level
than thought. Consequently, the World Health Organization
(WHO) classification of renal cell tumors has just recently been
modified (Inamura, 2017). The major current subtypes are clear
cell RCC (ccRCC, proximal tubule origin), papillary RCC (pRCC,
proximal tubule origin), and chromophobe RCC (chRCC,
collecting duct origin). ccRCC is a hypervascularized (fragile
thin-walled, staghorn-shaped vasculature). Possible causes of
ccRCC are mutations in the VHL gene (90%) as well as
genetic aberrations of mTOR pathway proteins (Low et al., 2016;
Inamura, 2017; Shingarev and Jaimes, 2017). Type 1 pRCC
is characterized by MET proto-oncogene-activating mutations
and type 2 with activation of the NRF2/antioxidant response
element pathway due to the increased oxidative stress. In contrast
to ccRCC, pRCC is characterized as hypovascularized region
compared to the adjacent parenchyma (Herts et al., 2002). chRCC
is a rare cancer and the least aggressive of all RCC subtypes. It is
characterized unlike ccRCC by thick-walled blood vessels (Low
et al., 2016; Inamura, 2017; Shingarev and Jaimes, 2017). Finally,
ccRCC shows a less favorable outcome compared with pRCC and
chRCC and has a greater propensity to metastasize (Low et al.,
2016; Inamura, 2017; Shingarev and Jaimes, 2017).
Complete surgical tumor resection (radical or partial
nephrectomies) remains the standard of care for all localized
RCCs. Resection of smaller solitary tumors offers a cure for most
patients (Autorino et al., 2017). However, this procedure often
results in nephron loss as well as a decreased glomerular filtration
rate in CKD stage 3 or higher associated with cardiovascular
complications, including death (Weight et al., 2010). In the case
of unresectable or metastatic RCC, a systemic immunotherapy
(IL-2, severe toxicity) or systemic treatment with antiangiogenic
factors (frequently leads to hypertension and proteinuria) or
mTOR inhibitors is required (Sánchez-Gastaldo et al., 2017;
Shingarev and Jaimes, 2017). It should be noted that a large
variety of cancers as well as different cancer therapies cause by
themselves acute kidney injury and/or CKD through several
mechanisms (Małyszko et al., 2017).
Collectively, kidney diseases including kidney cancer
represent a major socio-economic burden for which no effective
therapy is available. This illustrates the importance to identify
early markers of RCC and to better understand on a molecular
basis CKD as well as the regenerative potential of the kidney
to elucidate new therapeutic targets to delay late stage CKD
progression, to stop CKD progression or in the best case to
reverse kidney injury.
Relevance of aGPCRs in Cancer
The GPCR superfamily is currently responsible for the
therapeutic effect of 33% of all drugs approved by the U. S.
Food and Drug Administration (FDA) (Santos et al., 2017). Thus,
GPCRs represent the most successful class of pharmaceutical
targets. While only a handful of GPCRs have been demonstrated
to be oncology drugs, GPCRs play key roles in cancer and
thus pharmacological modulation of GPCR function has great
potential for the development of novel anti-cancer therapeutics
(Nieto Gutierrez and McDonald, 2017). Notably, there is also
published evidence for the role of aGPCRs in cancer suggesting
them as attractive drug targets. For example, increased expression
levels ofADGRG1,ADGRE5, andADGRF5 has been detected in a
variety of human cancers such as glioma (ADGRG1) (Shashidhar
et al., 2005), gastric (Liu et al., 2005), pancreatic (He et al.,
2015), esophageal (Aust et al., 2002), prostate (Ward et al.,
2011), colorectal carcinomas (Steinert et al., 2002) (ADGRE5),
and breast cancer (ADGRF5) (Tang et al., 2013). Moreover,
their importance in tumorigenesis has been substantiated in
xenograft tumor models. ADGRG1 knockdown resulted in
melanoma growth inhibition and regression (Ke et al., 2007),
while knockdown of the other 2 aGPCRs reduced lung (ADGRF5)
(Tang et al., 2013) and/or bone metastasis (ADGRE5, ADGRF5)
(Ward et al., 2011; Tang et al., 2013). Detailed in vitro and in vivo
analyses further indicated that ADGRG1 is a prosurvival factor
in cancer cells and promotes anchorage-independent growth (Ke
et al., 2007) whereas ADGRE5 (Ward et al., 2011) and ADGRF5
(Tang et al., 2013) regulate RhoA-dependent cell migration and
invasion.
RELEVANCE OF AGPCRS IN KIDNEY
DISEASE INCLUDING KIDNEY CANCER
Literature-Based Evidence Supported by
Database Information
As detailed below, our literature search identified publications
describing five aGPCRs correlated with kidney disease including
renal cancer: Adgrb1, Adgrg2 (Gpr64), Adgrl4, Adgrg3, and
Adgrf5.
Adgrb1 Suppresses RCC Angiogenesis
It is well known that new vascular formation (angiogenesis) is
required for tumor growth, invasion and metastasis (Carmeliet
and Jain, 2000). This process is directly promoted by VEGF
(Carmeliet, 2005). Yet, there are also a large variety of
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other factors that control tumor angiogenesis including Adgrb1
(Mathema and Na-Bangchang, 2017). Izutsu and coworkers
demonstrated by quantitative RT-PCR a 4-fold decrease in
ADGRB1 expression in RCC tissue compared to normal kidney
tissue, whereby ADGRB1 mRNA and protein expression were
lower in advanced RCC than in localized RCC tissues. Moreover,
the authors identified a negative correlation between microvessel
density and ADGRB1 protein expression. VEGF expression was
not affected (Izutsu et al., 2011). These data suggested that
downregulation of ADGRB1 during RCC contributes to an
improved tumor angiogenesis and thus enhanced tumor growth.
This is in agreement with the previous findings of Kudo and
coworkers who studied the potential of ADGRB1 as an anti-
angiogenic factor in RCC based on the known inverse correlation
of its expression with vascular density in other tumor types
(Kudo et al., 2007). They demonstrated in an in vivo tumor
model (subcutaneous inoculation of the RCC cell line Renca)
that ADGRB1 overexpression in Renca reduced tumor growth
due to reduced microvessel density which was associated with
reduced VEGF expression levels (Kudo et al., 2007). The role of
ADGRB1 is further supported by the FireBrowse database which
indicates that ADGRB1 is downregulated in chRCC (0.010-fold,
Table 2) and the cBio database indicating a mutation rate of
11% in chRCC. The observed downregulation of ADGRB1 in
chRCC might be an explanation for an increased vascularization
associated with chRCC (Low et al., 2016; Inamura, 2017;
Shingarev and Jaimes, 2017) and is consistent with no change
in hypovascularized pRCC (Herts et al., 2002). The lack of
downregulation in hypervascularized ccRCC might be due to the
different types of vessels (fragile vs. thick-walled; Low et al., 2016;
Inamura, 2017; Shingarev and Jaimes, 2017).
Adgrg2 Is Involved in Tumor Invasiveness
ADGRG2 is highly expressed in several human cancer cell lines
including 8 human RCC cell lines: CAKI-1, 786-0, A498, ACHN,
SN12-C, (all ccRCC), TK-10, RXF 393, and UO-31 (Richter et al.,
2013). In addition, it is overexpressed in Ewing’s sarcoma cell
lines (Richter et al., 2013). Ewing’s sarcoma is an aggressive,
small round-cell tumor with a strong potential to metastasize.
Typically it arises from the trunk and long bones of children or
young adults (Toomey et al., 2010). Yet, it can also primarily
occur in soft tissues, like the kidney (extra-skeletal Ewing’s
sarcomas), whereby its cellular origin is still unknown (Faizan
et al., 2014). Richter and coworkers demonstrated that inhibition
of Adgrg2 expression impaired colony formation in vitro (A673,
SB-KMS-KS1 and TC-71) and suppressed local tumor growth
and metastasis in an immunodeficient mouse xenograft model
of human cancer [SB-KMS-KS1/Rag2(−/−)γC(−/−)]. Finally, the
authors present evidence that Adgrg2 regulates invasiveness and
metastatic spread via induction of placental growth factor (PGF)
and matrix metalloproteinase 1 (Mmp-1) expression (Richter
et al., 2013). Consequently, the FireBrowse database shows that
ADGRG2 is only upregulated in ccRCC (2.34, Table 2), the
most metastatic RCC subtype (Low et al., 2016; Inamura, 2017;
Shingarev and Jaimes, 2017).
In addition, Nephroseq data suggest that ADGRG2 is
upregulated in diabetic nephropathy (human, mouse model),
CKD (human) as well as in the mouse Berthier model of
lupus nephritis with proteinuria. This finding is in agreement
with the fact that these diseases as well as RCC are associated
with abnormal expression levels of MMPs (Nakamura et al.,
2000; Catania et al., 2007; Jiang et al., 2010), including MMP-1
(Nakamura et al., 1993, 2000; Bhuvarahamurthy et al., 2006)
which is known to be regulated by Adgrg2 (Richter et al.,
2013). In addition, it has been demonstrated that, despite the
large number of MMPs known to be expressed in the healthy
kidney (Catania et al., 2007), changes in a single MMP can
cause kidney disease (Cheng et al., 2006). Moreover, it has been
shown that diabetes and systemic lupus erythematosus can cause
CKD through excessive levels of blood glucose or deposition
of immune complexes, respectively, resulting in defects in the
basement membrane, podocyte effacement, increase inmesangial
cell number and extracellular matrix (Fibbe and Rabelink, 2017;
Sharaf El Din et al., 2017). Ultimately, these conditions lead to
scarring and stiffening of the glomerulus (glomerulosclerosis),
tubulointerstitial fibrosis and CKD (Meguid El Nahas and Bello,
2005).
Adgrl4 Correlates with Better Prognosis in
ccRCC
As described above in the section about kidney development,
Adgrf5/Adgrl4 double knockout mice exhibit significantly
reduced kidney function. Around half of the double-deficient
mice died perinatally, while the other half showed growth
impairment and all died within 3 weeks to 3 months
postnatally. The analysis of 7 weeks-old mice revealed massive
proteinuria and uremia. Analyses of 4 weeks-old mice revealed
a set of pathological features indicating glomerular thrombotic
microangiopathy: schistocytes in the subendothelial zone of the
glomerular capillaries, loss of endothelial fenestration and fusion
of podocytes foot processes (Lu et al., 2017). Notably, even
though Adgrl4 and Adgrf5 are highly expressed in endothelial
cells, endothelial-specific deletion of Adgrf5/Adgrl4 utilizing VE-
Cad-Cre mice resulted in no renal phenotype. This suggests that
at least one of these aGPCRs might have a function in a renal cell
type.
A possible role of ADGRL4 in renal cancer has been proposed
by Masiero and collaborators. They analyzed the expression
profile of 1,080 primary human cancer samples including 170
ccRCC samples (Masiero et al., 2013). Utilizing a validated anti-
ADRGL4 antibody they detected ADGRL4 expression in the
endothelial cells and pericytes of all investigated normal and
pathological tissues. In ccRCC samples, ADGRL4 expression
was significantly higher than in the healthy control and its
expression level correlated positively with ccRCC microvessel
density. Importantly, the authors demonstrated that ADGRL4 is
required for proper endothelial sprouting and vessel formation in
vitro and in vivo and that its inhibition drastically reduced tumor
growth improving survival (Masiero et al., 2013). FireBrowse data
confirm this observation indicating an upregulation (2.13-fold,
Table 2) only in the hypervascularized ccRCC subtype (Low et al.,
2016; Inamura, 2017; Shingarev and Jaimes, 2017). It should be
noted that ADGRL4 is downregulated (0.179-fold) and mutated
(11%) in chRCC (Table 2), which might be explained, similarly
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as for ADGRB1, by the different types of vessels (fragile vs. thick-
walled; Low et al., 2016; Inamura, 2017; Shingarev and Jaimes,
2017).
Besides a role in kidney, ADGRL4 upregulation is according
to the Neprhoseq database associated with IgA nephropathy (33
human samples, 2.757 fold change, p= 5.18E-12) as well as lupus
nephritis (46 human samples, 5.493 fold change, p = 2.46E-7).
In addition, it has been associated with diabetic nephropathy
in mice (39 samples, 1.525 fold change, p = 0.002) but not in
humans (22 samples,−2.116 fold change, p = 0.999). Diabetic
nephropathy, IgA nephropathy and lupus nephritis are all
glomerular diseases in which sclerosis, increases in the mesangial
matrix and hypercellularity of the mesangial cells are common
pathological features (Meguid El Nahas and Bello, 2005; Fibbe
and Rabelink, 2017; Sharaf El Din et al., 2017). Yet, while Adgrl4
is clearly associated to endothelial cells and the microvasculature,
there appears no common phenotype in regards to an increased
microvascular density (as in hypervascularized ccRCC). This
suggests, similar as the lack of a renal phenotype in conditional
Adgrf5/Adgrl4 x VE-Cad-Cre mice (see above), that Adgrl4 has
a so far unknown function in a non-endothelial type. It should
be once more noted that according to EURExpress (sections 5–
8, 14–17) Adgrl4 is detected in the developing metanephros of
E14.5 mice. Yet, based on these data it is difficult to determine if
Adgrl4 is expressed in cells other than the endothelial cells of the
microvasculature.
Adgrg3 and Its Relation with Diabetic
Nephropathy
Adgrg3 is highly expressed in immune cells, but its function
remains largely unknown (Peng et al., 2011). Consistent with
the fact that the kidney develops macrophage-associated local
inflammation in response to metabolic disorders, such as insulin
resistance and diabetes (Navarro-González andMora-Fernandez,
2008; Declèves and Sharma, 2015), Adgrg3 is according to
the Nephroseq database upregulated in the mouse model of
diabetic nephropathy (12 samples, 2.938 fold change, p = 2.55E-
6). Loss of function experiments revealed that Adgrg3 has a
crucial role in maintaining normal splenic architecture and
regulating B cell development (Wang et al., 2013). Notably, Shi
and coworkers reported recently that more (2-fold) macrophages
invaded the kidney of Adgrg3 knockout mice on high-fat diet
(HFD) compared to HFD wildtype mice (Shi et al., 2016). This
phenotype was correlated to higher expression levels of the
inflammatory factor TNF-α. Yet, major metabolic phenotyping
showed no difference between Adgrg3 knockout and wildtype
mice on HFD.
In RCCs, ADGRG3 is according to the FireBrowse database
upregulated in all three RCC subtype with the highest expression
in chRCC (3.89-fold, Table 2). This is consistent with the fact
that immune cells and inflammatory processes significantly
contribute to RCC development and disease progression (de
Vivar Chevez et al., 2014).
Additional Database Information
Overall, the data obtained from the utilized databases indicate
that almost all aGPCRs are associated to kidney diseases
including APOL1-associated kidney disease, ccRCC, chRCC,
CKD, diabetic nephropathy, focal segmental glomerulosclerosis
(FSGS), hypertension-injured kidney, IgA nephropathy,
lupus nephritis, minimal change disease, membranous
glomerulopathy, pRCC, and vasculitis-injured kidney. Below
we discuss the diseases to which expression changes of several
aGPCRs have been associated.
CKD
Long-term kidney damage independent of its origin progressively
leads to a chronic disease state characterized by an irreversibly
low glomerular filtration rate (Meguid El Nahas and Bello,
2005). According to the Nephroseq database, 18 out of 33
human aGPCRs are upregulated in CKD compared with
healthy counterparts. Additionally, in two thirds of the cases
(12 out of 18), the fold change increase is >3. The altered
expression of that many aGPCRs is most likely a reflection
of the large variety of etiologies underlying CKD and the
multiple common pathophysiological processes involved such as
inflammation, ischemia, hypoxia, fibrosis, and metabolic waste
accumulation.
Lupus Nephritis, Diabetic Nephropathy, IgA
Nephropathy
These are the kidney diseases that are associated with
upregulation of a larger number of aGPCRs. Moreover, they
exhibit similar aGPCR signatures which might reflect that
all these diseases are glomerular diseases sharing common
pathological features such sclerosis, increases in the mesangial
matrix and hypercellularity of the mesangial cells (Meguid
El Nahas and Bello, 2005; Fibbe and Rabelink, 2017; Sharaf
El Din et al., 2017). Increased expression levels were found
for ADGRL2, ADGRL4, ADGRE1, ADGRE5, ADGRG2, and
ADGRG6 in lupus nephritis and diabetic nephropathy, whereby
ADGRL2, ADGRL4 and ADGRE5 were also upregulated in IgA
nephropathy (Table 2). As described above, altered expression
of Adgrg2 reflects the involvement of MMPs in these diseases
(Nakamura et al., 1993, 2000; Bhuvarahamurthy et al., 2006;
Catania et al., 2007; Jiang et al., 2010; Richter et al., 2013).
Altered expression of ADGRE1 and ADGRE5 is most likely due
to inflammatory processes underlying the progression of the
three diseases (Galkina and Ley, 2006; Imig and Ryan, 2013).
Adgre1 is in mice a macrophage marker (Lin et al., 2010)
and in humans a marker of eosinophilic granulocytes (Hamann
et al., 2007). Adgre5 is widely expressed along the lymphoid and
myeloid lineages (Hamann et al., 2015). Consequently, Adgre5 is
upregulated in autoimmune diseases (Wandel et al., 2012; Lin
et al., 2017). In contrast, the role of ADGRL4 in these diseases
remains unclear as discussed above. In regards to ADGRL2 and
ADGRG6 no published information is available that would allow
to conclude what role theymight play.Adgrl2 has previously been
associated with EMT in chicken valve heart development (Doyle
et al., 2006) and Adgrg6 with heart trabeculation and myelination
(Patra et al., 2014).
RCCs
According to the here analyzed databases aGPCRs which are
related to vascularization (Adgre1, Adgre5, Adgra2) (Wang et al.,
2005; Cullen et al., 2011; Wandel et al., 2012) or inflammatory
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processes (Adgre1, Adgre2, Adgre5) (Gray et al., 1996; Taylor
et al., 2005; Hamann et al., 2007; Kuan-Yu et al., 2017) are
>2.5-fold upregulated in ccRCC (Table 2). This reflects the high
degree of vascularization of ccRCCs (Prasad et al., 2006) and the
role of inflammatory related gene expression in its progression
(Tan et al., 2011). A role of these genes in vascular and/or
inflammation-mediated kidney diseases is further substantiated
by the associations with diabetes nephritis (ADGRE1, ADGRE5),
lupus nephritis (ADGRE1, ADGRE2, ADGRE5), renal vasculitis
(ADGRE2, ADGRE5), IgA nephropathy (ADGRE5) and renal
hypertension (ADGRE5). Furthermore, the hypoxia associated
aGPCRs ADGRB3 (Kee et al., 2004) and ADGRD1 (Bayin
et al., 2016) were >2.5-fold downregulated. In addition, the
aGPCRs ADGRA1, ADGRF1, ADGRF3, and ADGRV1 were
downregulated for which currently no role can be hypothesized.
In contrast to ccRCC, for chRCC it has been found
that the majority of affected aGPCRs (>2.5-fold change) are
downregulated (12 out of 15, Table 2). The major known
differences between ccRCC and chRCC ist that chRCC is less
metastatic, less vascularized and exhibits instead of fragile vessels
more thick-walled vessels. Consequently, proangiogenic aGPCRs
were not upregulated. In addition, expression of ADGRG1,
which promotes cell adhesion (Hamann et al., 2015), is strongly
upregulated and might explain the lower metastatic character
of chRCC. Yet, the pro-migratory aGPCR ADGRG3 is highly
expressed. Collectively, it appears impossible to extrapolate the
role of the affected aGPCRs in chRCC without more detailed
studies. The same is true for pRCCs, in which 10 aGPCRs were
>2.5-fold down- and 5 aGPCRs upregulated. Consistent with
its hypoplastic characteristic, the proangiogenic ADGRL4 was
downregulated. Yet, the pro-angiogenic factors ADGRE1 and
ADGRE5 were upregulated. Note, the FireBrowse data have to be
dealt with carefully as no p-values are provided.
Overall, it is apparent that in RCCs the majority of aGPCRs
is downregulated (28 out of 40), which is in agreement with
the described cellular functions of aGPCRs, which for example
mediate cell adhesion and directed cell division (Hamann
et al., 2015); processes often misregulated in RCCs. Among the
upregulated a GPCRs are consequently aGPCRs that promote
angiogenesis (ADGRE1, ADGRE5, ADGRA2) and inflammation
(ADGRE1, ADGRE2, ADGRE5) or act in contrast to most
other aGPCRs as anti-adhesive molecules (ADGRG1). It has
for example been shown that ADGRG1 activation promotes
melanoma cell migration (Chiang et al., 2017) and is required
for proper β-cell proliferation (Dunér et al., 2016). Yet, it is
noteworthy that the cellular functions of aGPCRs are still poorly
characterized and thus the kidney might provide a chance to
better understand the distinct roles of aGPCRs.
CONCLUSION II
Our analysis of publicly available data revealed that the role of
aGPCRs is also poorly characterized in kidney disease including
cancer. However, while the data in the literature is sparse and
not always in agreement with available “Omics” data, the publicly
available data support the conclusion that aGPCRs are involved
in the pathogenesis of a variety kidney diseases. Yet, it needs
to be clarified if the majority of the listed associations are due
to alterations in vascularization or inflammation of the diseased
kidney or if aGPCRs play additional underappreciated kidney-
specific roles.
FUTURE DIRECTIONS
Our analysis indicates that a large number of aGPCRs is
associated to kidney development and a variety of kidney
diseases suggesting an underappreciated role of aGPCRs in
kidney development, physiology and pathophysiology. Due
to the limited spatio-temporal expression data for aGPCRs
in the kidney it is difficult to conclude if certain aGPCRs
are de novo expressed during a disease or whether it is a
question of reactivation, for example in the context of a fetal
gene program. Thus, it is important to generate adequate
tools (e.g., validated antibodies and reporter lines) to better
characterize the expression patterns of aGPCRs. Considering that
multiple single aGPCR knockout mouse lines exhibit no obvious
phenotype, further analysis might provide information regarding
complementary aGPCRs with compensatory functions. However,
it should also be considered that the lack of phenotypes
might be due to the lack of a vigorous investigation (e.g.,
kidney not analyzed, kidney function not challenged) or to an
incomplete gene deletion. For example it has been shown that
the N-terminal and C-terminal fragment of aGPCRs can have
independent functions (Patra et al., 2013). In addition, genetic
manipulations of an aGPCR might not affect alternative splice
forms (Bjarnadóttir et al., 2007) or induce expression of artificial
alternative splice forms. Cell-type specific expression analysis
will also help to determine if aGPCRs have a primary role or
whether their association is rather due to bystander effects. This,
however, appears rather unlikely as aGPCRs regulate a variety of
cellular processes known to be essential to kidney development,
physiology and pathophysiology. Collectively, it is important
that experts in kidney development and disease collaborate with
experts in the field of aGPCRs to elucidate the role of aGPCRs in
kidney development, physiology and pathophysiology in order to
determine if this knowledge can be utilized for better diagnosis
and/ or treatment of kidney diseases including RCCs.
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